MedPath

Ceftriaxone

Generic Name
Ceftriaxone
Brand Names
Rocephin
Drug Type
Small Molecule
Chemical Formula
C18H18N8O7S3
CAS Number
73384-59-5
Unique Ingredient Identifier
75J73V1629
Background

Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.

Indication

Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms. Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabilis, E. coli, Klebsiella spp, M. catarrhalis, B. burgdorferi, and some oral anaerobes.

Associated Conditions
Abscess Brain, Bacterial Endocarditis, Bacterial Infections, Bacterial Sinusitis, Bone and Joint Infections, Chancroid, Community Acquired Pneumonia (CAP), Conjunctivitis gonococcal neonatal, Epididymitis, Epiglottitis, Gonococcal arthritis, Gonococcal infection of pharynx, Gonococcal pelvic inflammatory disease, Intraabdominal Infections, Lower respiratory tract infection bacterial, Lyme Neuroborreliosis, Meningitis, Bacterial, Ophthalmia neonatorum due to gonococcus, Postoperative Infections, Prosthetic Joint Infections, Sepsis Bacterial, Septic Arthritis, Shigellosis, Skin and Subcutaneous Tissue Bacterial Infections, Syphilis, Vulvovaginitis gonococcal, Whipple Disease, Bacterial otitis media, Complicated Urinary Tract Infection caused by susceptible bacteria, Disease caused by Salmonella typhi, Susceptible Bacterial Infections, Uncomplicated Gonorrhea, Uncomplicated Urinary tract infection bacterial
Clinical Trials
Related News

First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition

Phase 3
Conditions
Antibiotic Resistance
Malnutrition Severe
Antibiotic Toxicity
Interventions
Drug: Benzyl penicillin
Other: Placebo
First Posted Date
2017-06-02
Last Posted Date
2020-05-19
Lead Sponsor
University of Oxford
Target Recruit Count
2000
Registration Number
NCT03174236
Locations
🇰🇪

Mbagathi Hospital, Nairobi, Kenya

🇰🇪

Coast General Hospital - Study site, Mombasa, Kenya

🇰🇪

Mbagathi District Hospital, Nairobi, Kenya

and more 4 locations

Ceftriaxone and Jaundice in Neonates

Completed
Conditions
Jaundice and Sepsis in Neonates
Interventions
First Posted Date
2017-04-28
Last Posted Date
2021-04-06
Lead Sponsor
University of Rochester
Target Recruit Count
27
Registration Number
NCT03133637
Locations
🇺🇸

University of Rochester Medical Center, Rochester, New York, United States

Antibiotics to Decrease Post ERCP Cholangitis

Phase 4
Recruiting
Conditions
Cholangitis
Interventions
First Posted Date
2017-03-22
Last Posted Date
2023-03-06
Lead Sponsor
University of Southern California
Target Recruit Count
200
Registration Number
NCT03087656
Locations
🇺🇸

Los Angeles County Hospital, Los Angeles, California, United States

RCT to Determine the Efficacy of Combining Hemospray With Medical Treatment in Acute Variceal Bleeding

Not Applicable
Completed
Conditions
Variceal Hemorrhage
Interventions
Device: Hemospray
Biological: Blood transfusion
First Posted Date
2017-02-23
Last Posted Date
2017-11-14
Lead Sponsor
Theodor Bilharz Research Institute
Target Recruit Count
105
Registration Number
NCT03061604
Locations
🇧🇪

Erasme Hospital , ULB, Brussels, Belgium

🇪🇬

Theodor Bilharz Research Institute, Giza, Egypt

Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis

Phase 4
Conditions
Critical Illness
Mechanical Ventilation Complication
Interventions
Drug: placebo
First Posted Date
2017-01-06
Last Posted Date
2022-08-17
Lead Sponsor
University Hospital, Lille
Target Recruit Count
154
Registration Number
NCT03012360
Locations
🇫🇷

Hôpital Roger Salengro, CHRU, Lille, France

Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery

Not Applicable
Recruiting
Conditions
Propionibacterium Infection
Interventions
First Posted Date
2016-12-19
Last Posted Date
2023-05-10
Lead Sponsor
Université de Montréal
Target Recruit Count
88
Registration Number
NCT02996656
Locations
🇨🇦

Hôpital du Sacré-Cœur de Montréal, Montréal, Quebec, Canada

Optimising Antibiotic Treatment for Sick Malnourished Children

Phase 2
Conditions
Malnutrition
Interventions
First Posted Date
2016-04-21
Last Posted Date
2017-07-02
Lead Sponsor
University of Oxford
Target Recruit Count
81
Registration Number
NCT02746276
Locations
🇰🇪

KEMRI WT Clinical Trials Facility, Kilifi, Kenya

The Optimal Time for Intravenous Antibiotic Prophylaxis in Elective Cesarean Section

Phase 2
Conditions
Endometritis
Interventions
First Posted Date
2016-04-19
Last Posted Date
2016-04-19
Lead Sponsor
Cairo University
Target Recruit Count
600
Registration Number
NCT02742948

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Phase 3
Recruiting
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Other: No systemic corticosteroid
Other: No antiviral agent for COVID-19
Other: No immune modulation for COVID-19
Drug: Standard course macrolide
Other: No antiviral agent for influenza
Drug: Local standard venous thromboprophylaxis
Other: No immunoglobulin
Other: No simvastatin
Other: No cysteamine
Other: No Immune Modulator for Influenza
Other: No vitamin C
Other: No antiplatelet
Procedure: Clinician-preferred mechanical ventilation strategy
Other: No renin-angiotensin system inhibitor
Other: No endothelial modulator
Drug: Extended course macrolide
Biological: Convalescent plasma
Drug: Therapeutic dose anticoagulation
Procedure: Protocolised mechanical ventilation strategy
Drug: P2Y12 inhibitor
Drug: Conventional low dose thromboprophylaxis
Biological: Delayed administration of convalescent plasma
Drug: Intermediate dose thromboprophylaxis
Drug: ARB + DMX-200
Drug: Amoxicillin-clavulanate
Drug: Continuation of therapeutic dose anticoagulation
First Posted Date
2016-04-13
Last Posted Date
2024-07-12
Lead Sponsor
UMC Utrecht
Target Recruit Count
20000
Registration Number
NCT02735707
Locations
🇨🇦

Toronto Western Hospital, Toronto, Ontario, Canada

🇺🇸

University of Illinois Health, Chicago, Illinois, United States

🇦🇺

Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia

and more 405 locations

Impact of the Choice of 3rd Generation Cephalosporins on the Emergence of Resistance in the Microbiota Intestinal.

Phase 3
Completed
Conditions
Emergence of Bacterial Resistance to Antibiotics
Interventions
First Posted Date
2016-01-20
Last Posted Date
2018-05-21
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
22
Registration Number
NCT02659033
Locations
🇫🇷

Hôpital Bichat, Paris, France

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy